Protective effect of l-kynurenine and probenecid on 6-hydroxydopamine-induced striatal toxicity in rats: Implications of modulating kynurenate as a protective strategy

Neurotoxicology and Teratology

Volumn 33, Issue 2, 2011, Pages 303-312

  Silva Adaya, Daniela ^a   Pérez De La Cruz, Verónica ^a   Villeda Hernández, Juana ^a   Carrillo Mora, Paul ^a   González Herrera, Irma Gabriela ^a   García, Esperanza ^a   Colín Barenque, Laura ^b   Pedraza Chaverrí, José ^c   Santamaría, Abel ^a  

^a NATIONAL INSTITUTE OF NEUROLOGY AND NEUROSURGERY   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c Universidad Nacional Autonoma de Mexico Facultad de Quimica   (Mexico)

Author keywords

6 Hydroxydopamine; Kynurenine; Kynurenine pathway; Neuroprotection; Neurotoxicity; Parkinson's disease model; Probenecid

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; BUNGAROTOXIN RECEPTOR; DOPAMINE; GLIAL FIBRILLARY ACIDIC PROTEIN; GLUTAMIC ACID; HOMOVANILLIC ACID; KYNURENINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; OXIDOPAMINE; PROBENECID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BEHAVIOR CHANGE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DOPAMINERGIC SYSTEM; GLIOSIS; MALE; MOTOR DYSFUNCTION; NERVE DEGENERATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; RAT;

ANIMALS; BEHAVIOR, ANIMAL; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; KYNURENIC ACID; KYNURENINE; MALE; NEUROPROTECTIVE AGENTS; NEUROTOXICITY SYNDROMES; OXIDOPAMINE; PROBENECID; RATS; RATS, WISTAR;

ANIMALIA; RATTUS; RODENTIA;

EID: 79953325908     PISSN: 08920362     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ntt.2010.10.002     Document Type: Article

References (50)

1. Aponso P.M., Faull R.L.M., Connor B. Increased progenitor cell proliferation and astrogenesis in the partial progressive 6-hydroxydopamine model of Parkinson's disease. Neuroscience 2008, 151:1142-1153.
2. Beal M.F. Experimental models of Parkinson's disease. Nat Rev 2001, 2:325-332.
3. Berger K., Przedborski S., Cadet J.L. Retrograde degeneration of nigrostriatal neurons induced by intrastriatal 6-hydroxydopamine injection in rats. Brain Res Bull 1991, 26:301-307.
4. Blandini F., Levandis G., Bazzini E., Nappi G., Armentero M.T. Time-course of nigrostriatal damage, basal ganglia metabolic changes and behavioural alterations following intrastriatal injection of 6-hydroxydopamine in the rat: new clues from an old model. Eur J Neurosci 2007, 25:397-405.
5. Blum D., Torch S., Lambeng N., Nissou M., Benabid A.L., Sadoul R., et al. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog Neurobiol 2001, 65:135-172.
6. Bové J., Prou D., Perier C., Przedborski S. Toxin-induced models of Parkinson's disease. NeuroRx 2005, 2:484-494.
7. Calkins M.J., Vargas M.R., Johnson D.A., Johnson J.A. Astrocyte-specific overexpression of Nrf2 protects striatal neurons from mitochondrial complex II inhibition. Toxicol Sci 2010, 115:557-568.
8. Carpenedo R., Pittaluga A., Cozzi A., Attucci S., Galli A., Raiteri M., et al. Presynaptic kynurenate-sensitive receptors inhibit glutamate release. Eur J Neurosci 2001, 13:2141-2147.
9. Carrillo-Mora P., Méndez-Cuesta L.A., Pérez-De La Cruz V., Fortoul-van Der Goes T.I., Santamaría A. Protective effect of systemic l-kynurenine and probenecid administration on behavioural and morphological alterations induced by toxic soluble amyloid beta (25-35) in rat hippocampus. Behav Brain Res 2010, 210:240-250.
10. Costa G., Abin-Carriquiry J.A., Dajas F. Nicotine prevents striatal dopamine loss produced by 6-hydroxydopamine lesion in the substantia nigra. Brain Res 2001, 888:336-342.
11. Decker D.E., Althaus J.S., Buxser S.E., VonVoigtlander P.F., Ruppel P.L. Competitive irreversible inhibition of dopamine uptake by 6-hydroxydopamine. Res Commun Chem Pathol Pharmacol 1993, 79:195-208.
12. Eng L.F., Ghirnikar R.S., Lee Y.L. Glial fibrillary acidic protein: GFAP-thirty-one years (1969-2000). Neurochem Res 2000, 25:1439-1451.
13. Foster A.C., Vezzani A., French E.D., Schwarcz R. Kynurenic acid blocks neurotoxicity and seizures induced in rats by the related brain metabolite quinolinic acid. Neurosci Lett 1984, 48:273-278.
14. García E., Limón D., Pérez-De La Cruz V., Giordano M., Díaz-Muñoz M., Maldonado P.D., et al. Lipid peroxidation, mitochondrial dysfunction and neurochemical and behavioural deficits in different neurotoxic models: protective role of S-allylcysteine. Free Radic Res 2008, 42:892-902.
15. Gigler G., Szenasi G., Simo A., Levay G., Harsing L.G., Sas K. Neuroprotective effect of l-kynurenine sulfate administered before focal cerebral ischemia in mice and global cerebral ischemia in gerbils. Eur J Pharmacol 2007, 564:116-122.
16. Goda K., Kishimoto R., Shimizu S., Hamane Y., Ueda M. Quinolinic acid and active oxygens. Possible contribution of active oxygens during cell death in the brain. Adv Exp Med Biol 1996, 398:247-254.
17. Hardeland R., Zsizsik B.K., Poeggeler B., Fuhrberg B., Holst S., Coto-Montes A. Indole-3-pyruvic and -propionic acids, kynurenic acid, and related metabolites as luminophores and free-radical scavengers. Adv Exp Med Biol 1999, 467:389-395.
18. Hilmas C., Pereira E.F., Alkondon M., Rassoulpour A., Schwarcz R., Albuquerque E.X. The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. J Neurosci 2001, 21:7463-7473.
19. Hlinak Z., Krejci I. Spontaneous alternation behaviour in rats: Kynurenic acid attenuated deficits induced by MK-801. Behav Brain Res 2006, 168:144-149.
20. Jakel R.J., Maragos W.F. Neuronal cell death in Huntington's disease: a potential role for dopamine. Trends Neurosci 2000, 23:239-245.
21. Kemp J.A., McKernan R.M. NMDA receptor pathways as drug targets. Nat Neurosci 2002, 5:1039-1042.
22. Kessler M., Terramani T., Lynch G., Baudry M. A glycine site associated with n-methyl-d-aspartic acid receptors: characterization and identification of a new class of antagonists. J Neurochem 1989, 52:1319-1328.
23. Lang A.E., Lozano A.M. Parkinson's disease. First of two parts. N Engl J Med 1998, 339:1030-1043.
24. Lang A.E., Lozano A.M. Parkinson's disease. Second of two parts. N Engl J Med 1998, 339:1044-1053.
25. Löschmann P.A., De Groote C., Smith L., Wüllner U., Fischer G., Kemp J.A., et al. Antiparkinsonian activity of Ro 25-6981, a NR2B subunit specific NMDA receptor antagonist, in animal models of Parkinson's disease. Exp Neurol 2004, 187:86-93.
26. Marin C., Rodríguez-Oroz M.C., Obeso J.A. Motor complications in Parkinson's disease and the clinical significance of rotational behavior in the rat: have we wasted our time?. Exp Neurol 2006, 197:269-274.
27. Miller J.M., MacGarvey U., Beal M.F. The effect of peripheral loading with kynurenine and probenecid on extracellular striatal kynurenic acid concentrations. Neurosci Lett 1992, 146:115-118.
28. Miranda A.F., Boegman R.J., Beninger R.J., Jhamandas K. Protection against quinolinic acid-mediated excitotoxicity in nigrostriatal dopaminergic neurons by endogenous kynurenic acid. Neuroscience 1997, 78:967-975.
29. Montastruc J.L., Rascol O., Senard J.M. Glutamate antagonists and Parkinson's disease: a review of clinical data. Neurosci Biobehav Rev 1997, 21:477-480.
30. Nash J.E., Brotchie J.M. Characterisation of striatal NMDA receptors involved in the generation of parkinsonian symptoms: intrastriatal microinjection studies in the 6-OHDA-lesioned rat. Mov Disord 2002, 17:455-466.
31. Nash J.E., Fox S.H., Henry B., Hill M.P., Peggs D., McGuire S., et al. Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease. Exp Neurol 2000, 165:136-142.
32. Nash J.E., Ravenscroft P., McGuire S., Crossman A.R., Menniti F.S., Brotchie J.M. The NR2B-selective NMDA receptor antagonist CP-101, 606 exacerbates l-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of l-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease. Exp Neurol 2004, 188:471-479.
33. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 1986, Academic Press, San Diego.
34. Pérez-De La Cruz V., Königsberg M., Santamaría A. Kynurenine pathway and disease: an overview. CNS Neurol Disord Drug Targets 2007, 6:398-410.
35. Poeggeler B., Rassoulpour A., Wu H.-Q., Guidetti P., Roberts R.C., Schwarcz R. Dopamine receptor activation reveals a novel, kynurenate-sensitive component of striatal n-methyl-d-aspartate neurotoxicity. Neuroscience 2007, 148:188-197.
36. Przedborski S., Levivier M., Jiang H., Ferreira M., Jackson-Lewis V., Donaldson D., et al. Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-OHDA. Neuroscience 1995, 67:631-647.
37. Quintero E.M., Willis L., Singleton R., Harris N., Huang P., Bhat N., et al. Behavioral and morphological effects of minocycline in the 6-hydroxydopamine rat model of Parkinson's disease. Brain Res 2006, 1093:198-207.
38. Rassoulpour A., Wu H.Q., Ferre S., Schwarcz R. Nanomolar concentrations of kynurenic acid reduce extracellular dopamine levels in the striatum. J Neurochem 2005, 93:762-765.
39. Robotka H., Sas K., Agoston M., Rozsa E., Szenasi G., Gigler G. Neuroprotection achieved in the ischaemic rat cortex with l-kynurenine sulphate. Life Sci 2008, 82:915-919.
40. Rodríguez E., Méndez-Armenta M., Villeda-Hernández J., Galván-Arzate S., Barroso-Moguel R., Rodríguez F., et al. Dapsone prevents morphological lesions and lipid peroxidation induced by quinolinic acid in rat corpus striatum. Toxicology 1999, 139:111-118.
41. Roghani M., Niknam A., Jalali-Nadoushan M.R., Kiasalari Z., Khalili M., Baluchnejadmojarad T., et al. Oral pelargonidin exerts dose-dependent neuroprotection in 6-hydroxydopamine rat model of hemi-parkinsonism. Brain Res Bull 2010, 82:279-283.
42. Santamaría A., Ríos C., Solís-Hernández F., Ordaz-Moreno J., González-Reynoso L., Altagracia M., et al. Systemic dl-kynurenine and probenecid pretreatment attenuates quinolinic acid-induced neurotoxicity in rats. Neuropharmacology 1996, 35:23-28.
43. Sas K., Robotka H., Rozsa E., Agoston M., Szenasi G., Gigler G. Kynurenine diminishes the ischemia-induced histological and electrophysiological deficits in the rat hippocampus. Neurobiol Dis 2008, 32:302-308.
44. Schober A. Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP. Cell Tissue Res 2004, 318:215-224.
45. Schwarcz R. The kynurenine pathway of tryptophan degradation as a drug target. Curr Opin Pharmacol 2004, 4:12-17.
46. Shastry B.S. Parkinson disease: etiology, pathogenesis and future of gene therapy. Neurosci Res 2001, 41:5-12.
47. Stone T.W. Development and therapeutic potential of kynurenic acid and kynurenine derivatives for neuroprotection. Trends Pharmacol Sci 2000, 21:149-154.
48. Stone T.W. Kynurenic acid antagonists and kynurenine pathway inhibitors. Expert Opin Investig Drugs 2001, 10:633-645.
49. Tobón-Velasco J.C., Silva-Adaya D., Carmona-Aparicio L., García E., Galván-Arzate S., Santamaría A. Early toxic effect of 6-hydroxydopamine on extracellular concentrations of neurotransmitters in the rat striatum: An in vivo microdialysis study. Neurotoxicology 2010, 31:715-723.
50. Vécsei L., Miller J., MacGarvey U., Beal M.F. Kynurenine and probenecid inhibit pentylenetetrazol- and NMDLA-induced seizures and increase kynurenic acid concentrations in the brain. Brain Res Bull 1992, 28:233-238.